Icoria Signs Licensing Agreement With Syngenta

Integrated systems biology company Icoria has licensed to Syngenta the exclusive rights to commercially develop 30 Icoria compounds believed to be active fungal inhibitors. Syngenta will evaluate the compounds over the course of 18 months and Icoria expects that Syngenta will select the most promising compounds for development and eventual commercial use as agricultural fungicides. Syngenta also has the right to commercially develop the compounds in human healthcare (antimicrobial use), animal health, household products, and industrial applications.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19205420&full=1)